Lupin launches Rufinamide Oral Suspension in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel® Oral Suspension, 40 mg/mL of Eisai Inc.

Rufinamide Oral Suspension (RLD Banzel®) had estimated annual sales of USD 72 million in the U.S. (IQVIA MAT April 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 858.00 as compared to the previous close of Rs. 851.90. The total number of shares traded during the day was 150810 in over 4594 trades.

The stock hit an intraday high of Rs. 865.55 and intraday low of 847.85. The net turnover during the day was Rs. 129432428.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 RufinamideOralSuspension ProductLaunch UnitedStates